Our success in 2011 gives us a strong position on which to build. In 2012, we will focus on the continued growth and leadership of our marketed products and the advancement of our strong pipeline.


Commercial Execution

  • Stabilized AVONEX market share
  • Introduced the AVONEX PEN to European markets and Canada
  • Hit key milestones important for unlocking the value of TYSABRI
    • JCV assay made commercially available in the US and EU
    • Product label updated in the EU and the US in 2012
  • Successful appeal of FAMPYRA in EU; launched in Germany with additional launches in 2012

Advance Late-Stage Pipeline

  • BG-12, oral MS candidate: potential launch 2013
  • Long-lasting factor VIII and factor IX program candidates for hemophilia: data readouts expected 2012
  • PEGylated interferon beta-1a for MS: phase III data expected 2013

Strengthen R&D/Early-stage Pipeline

  • Dexpramipexole in ALS: enrolled first phase III study; fastest enrollment in company history
  • Daclizumab-HYP: positive data readout from first registrational trial
  • Collaboration with Portola Pharmaceuticals to develop and commercialize an oral, highly selective Syk inhibitor
  • Collaboration in 2012 with Isis Pharmaceuticals for compound to target spinal muscular atrophy

Culture of Excellence

  • Focused strategic direction
  • Advanced in building a culture that attracts the best people
  • Better, crisper decision-making
  • Sense of accountability throughout the organization
  • Result: more nimble, focused and ambitious organization